Want to see HK:0719 full AI Analyst Report?
0719 Stock Chart & Stats
HK$6.67
HK$0.00(0.00%)
At close: 4:00 PM EST
HK$6.67
HK$0.00(0.00%)
Day’s Range― - ―
52-Week RangeHK$5.18 - HK$8.19
Previous CloseN/A
Volume2.84M
Average Volume (3M)1.49M
Market Cap
HK$9.09B
Enterprise ValueHK$6.69B
Total Cash (Recent Filing)HK$1.27B
Total Debt (Recent Filing)HK$1.93B
Price to Earnings (P/E)36.0
Beta0.70
Next Earnings
Aug 26, 2026EPS Estimate
0.2Next Dividend Ex-DateN/A
Dividend Yield2.81%
Share Statistics
EPS (TTM)0.37
Shares Outstanding195,000,000
10 Day Avg. Volume1,000,110
30 Day Avg. Volume1,490,646
Financial Highlights & Ratios
PEG Ratio-0.36
Price to Book (P/B)0.78
Price to Sales (P/S)0.47
P/FCF Ratio9.76
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.94
Revenue Forecast (FY)HK$9.35B
Bulls Say, Bears Say
Bulls Say
Diversified Product MixThe company's mix across APIs, finished formulations and chemical intermediates creates multiple, partially independent revenue streams serving both domestic and export pharma supply chains. This structural diversity reduces single-market exposure and supports steady demand from drug makers over the medium term.
Solid Balance SheetLeverage remains moderate and equity is substantial versus assets, providing financial flexibility. A reasonable debt/equity profile and positive ROE support capacity to fund operations, invest in capacity, and withstand industry cycles without immediate refinancing pressure over the next several months.
Positive Cash GenerationThe company is still generating positive operating and free cash flow and covers a meaningful share of reported earnings. That structural cash generation supports dividends, working capital and targeted capex, helping sustain operations and strategic initiatives despite profit cyclicality.
Bears Say
Sharp Revenue DeclineA ~33% TTM sales decline is a material structural headwind: it can erode scale economics, reduce bargaining power on input costs, and pressure margins and reinvestment capacity. If sustained, lower volumes imply slower recovery and could force strategic restructuring or pricing concessions.
Earnings ContractionA roughly 40% EPS decline signals material pressure on profitability beyond one-off items. Sustained earnings contraction limits retained earnings, reduces ROE and constrains the firm's ability to fund growth or increase dividends without drawing on balance sheet buffers.
Cash Flow Volatility And FCF DeclineRecent ~24% drop in FCF and prior periods of negative FCF indicate cash generation is inconsistent. Volatile FCF raises funding risk for capex, working capital and debt servicing if margins remain depressed, and reduces predictability for investors and management planning.
Shandong Xinhua Pharmaceutical Company Limited Class H News
0719 FAQ
What was Shandong Xinhua Pharmaceutical Company Limited Class H’s price range in the past 12 months?
Shandong Xinhua Pharmaceutical Company Limited Class H lowest stock price was HK$5.18 and its highest was HK$8.19 in the past 12 months.
What is Shandong Xinhua Pharmaceutical Company Limited Class H’s market cap?
Shandong Xinhua Pharmaceutical Company Limited Class H’s market cap is HK$9.09B.
When is Shandong Xinhua Pharmaceutical Company Limited Class H’s upcoming earnings report date?
Shandong Xinhua Pharmaceutical Company Limited Class H’s upcoming earnings report date is Aug 26, 2026 which is in 21 days.
How were Shandong Xinhua Pharmaceutical Company Limited Class H’s earnings last quarter?
Shandong Xinhua Pharmaceutical Company Limited Class H released its earnings results on Apr 28, 2026. The company reported HK$0.139 earnings per share for the quarter, missing the consensus estimate of HK$0.208 by -HK$0.069.
Is Shandong Xinhua Pharmaceutical Company Limited Class H overvalued?
According to Wall Street analysts Shandong Xinhua Pharmaceutical Company Limited Class H’s price is currently Overvalued.
Does Shandong Xinhua Pharmaceutical Company Limited Class H pay dividends?
Shandong Xinhua Pharmaceutical Company Limited Class H pays a Annually dividend of HK$0.172 which represents an annual dividend yield of 2.81%. See more information on Shandong Xinhua Pharmaceutical Company Limited Class H dividends here
What is Shandong Xinhua Pharmaceutical Company Limited Class H’s EPS estimate?
Shandong Xinhua Pharmaceutical Company Limited Class H’s EPS estimate is 0.2.
How many shares outstanding does Shandong Xinhua Pharmaceutical Company Limited Class H have?
Shandong Xinhua Pharmaceutical Company Limited Class H has 195,000,000 shares outstanding.
What happened to Shandong Xinhua Pharmaceutical Company Limited Class H’s price movement after its last earnings report?
Shandong Xinhua Pharmaceutical Company Limited Class H reported an EPS of HK$0.139 in its last earnings report, missing expectations of HK$0.208. Following the earnings report the stock price went up 0.167%.
Which hedge fund is a major shareholder of Shandong Xinhua Pharmaceutical Company Limited Class H?
Currently, no hedge funds are holding shares in HK:0719
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Shandong Xinhua Pharmaceutical Company Limited Class H Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
30.34%
12-Months-Change
Fundamentals
Return on Equity
2.81%
Trailing 12-Months
Asset Growth
3.49%
Trailing 12-Months
Company Description
Shandong Xinhua Pharmaceutical Company Limited Class H
Shandong Xinhua Pharmaceutical Company Limited develops, manufactures, and sells bulk pharmaceuticals, preparations, and chemical products in the People's Republic of China, the Americas, Europe, and internationally. The company offers antipyretic and analgesic, cardiovascular and cerebrovascular, anti-infective, and central nervous drugs under the Xinhua brand; and contract manufacturing services for active pharmaceutical ingredients and pharmaceutical intermediates, OTC, and generics. It also provides ibuprofen bulk pharmaceutical products; and prepared Chinese herbal medicine for decoction, traditional Chinese medicine, chemical bulk drugs, chemical preparations, chemical raw materials, antibiotics, biochemical medicines, anesthetics, anti-psychotic drugs, pharmaceutical precursor chemicals, protein assimilation preparations, peptide hormones, medical toxic drugs, etc. In addition, the company offers raw materials and intermediates; internet data services, internet sales, and internet information services for pharmaceuticals and medical devices; veterinary drugs and fodders; bulk pharmaceutical and intermediates; steroid system apis and intermediates; and chemical raw materials. Further, the company produces and sells chemical products; exports and imports goods and technologies; and designs medical projects. Additionally, it engages in the property management, nonresidential real estate leasing, and housing leasing activities; certification and import and export business; electrical equipment engineering; installation and testing of chemical equipment; and manufacture of mechanical and electrical equipment, nonstandard equipment, as well as production and hardware and electrical equipment, and electrical installations equipment and manufacture; and sale of controller switching equipment. Shandong Xinhua Pharmaceutical Company Limited was founded in 1943 and is based in Zibo, the People's Republic of China.
Shandong Xinhua Pharmaceutical Company Limited Class H (0719) Earnings & Revenues
Technical Analysis
Guangzhou Baiyunshan Pharmaceutical Holdings Company
―
Livzon Pharmaceutical Group
―
Sihuan Pharmaceutical Holdings Group
―
China Resources Pharmaceutical Group Ltd.
―
Consun Pharmaceutical Group Ltd.
―